Custirsen Sodium

Summary

Custirsen Sodium (CHEMBL2219773) is a phase-3 clinical-stage oligonucleotide; indicated across 3 conditions including breast neoplasm and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2219773
Name	Custirsen Sodium
Type	Oligonucleotide
Max phase	3

Also known as: Custirsen sodium, ISIS 112989, ISIS-112989, Ogx 011, OGX-011, CUSTIRSEN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	2	MONDO:0021100	MONDO:0007254
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01083615	PHASE3	TERMINATED	A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT01578655	PHASE3	COMPLETED	Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
NCT00138658	PHASE1/PHASE2	COMPLETED	A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00138918	PHASE2	COMPLETED	Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
NCT00258375	PHASE2	COMPLETED	OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
NCT00258388	PHASE2	COMPLETED	Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00054106	PHASE1	COMPLETED	Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
NCT00471432	PHASE1	COMPLETED	OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).